By Sahil Kapoor, MBA, M.Tech; Manager, HITLAB India
HealthPatch MD- Continuous real time connection between doctors and patients
The burden of chronic illness is increasing at a rapid pace worldwide. Managing chronic conditions at home is an enormous challenge. How about a technology that can connect doctors to patients with 24/7 access to medical data? This will not only allow physicians to monitor their patients continuously, but also empower them to make prompt and reliable decisions. Such technologies have the potential to revolutionize telemetry in healthcare by simply streaming medical data in real time to provide valuable predictive insights.
Vital Connect, a California-based medical device company, has designed such a breakthrough technology. HealthPatch MD is a cutting-edge innovation that offers remote monitoring of multiple vital signs in real time and is well-suited for home as well as clinical settings.
This wireless and lightweight device consists of a reusable sensor module and a disposable patch. It adheres to the chest and continuously tracks comprehensive vital signs and biometrics, including single-lead ECG, heart rate (HR), HR variability (HRV), respiratory rate (RR), RR interval, skin temperature, posture, fall detection and activity with steps. The flexible adhesive patch can be worn under clothing for 24 hours, and even while bathing as well as exercising.
The sensor has a battery life of 48-72 hours. It employs Bluetooth 4.0 to connect to a mobile device that transfers information by Wi-Fi to the cloud (meeting HIPAA and data privacy guidelines). This makes it feasible for physicians to receive notifications whenever physiological data falls out of range. Consequently, doctors can intervene with suitable advice and medication. Also, patient data can be used to perform analytics.
HealthPatch MD, an FDA-approved biosensor, is available in United States, Europe, Japan, and Canada. It is a versatile device with reliable relay and cloud connectivity. Undoubtedly, HealthPatch MD is a state-of-the-art technology for transforming the healthcare industry.
To see the HealthPatch MD in action, click here.
By Sahil Kapoor, MBA, M.Tech; Manager, HITLAB India
ADAMM: An automated smart wearable technology for asthma monitoring and management
ASTHMA is a chronic lung disease that affects 24 million Americans. According to the Centers for Disease Control (CDC), one in 14 people have asthma and it is the third leading cause of hospital stays in children. Monitoring and managing asthma is undoubtedly a challenge these days because of busy lifestyles, which make it difficult to track triggers that provoke the condition.
This ailment is not only tough for adults to monitor; it is even harder for children. With recent advances in medical technology, wearables and biosensors are becoming a hot commodity for managing chronic conditions. These are like silver bullets that enable patients to self-manage the disease. Recently, a wearable called ADAMM (Automated Device for Asthma Monitoring and Management) was introduced, designed by Health Care Originals.
This intelligent asthma management device consists of an adhesive patch, web portal, and mobile app. The flexible patch with rechargeable battery can be worn anywhere on the upper torso, front or back. The device is embedded with a sensor and facilitates symptom detection (cough rates, respiration rate, heartbeat, and temperature), notifications on symptom deviation, inhaler detection, voice journaling and HIPAA compliant data storage.
Also embedded in this innovative wearable is a unique algorithm technology that processes data to provide valuable insights. ADAMM transmits data wirelessly to a mobile app, where it can remind the wearer to take medication, warn of possible asthma attacks and alert parents, if the wearer is a child. The web portal is also available to access data anytime and anywhere.
ADAMM is an award-winning technology that allows patients to avoid asthma flare-ups by monitoring early breathing issues. This device is a boon for asthma patients as it helps them to walk through smoke-filled casinos and crowded lanes with more confidence.
by Devmalya Sarkar, M.S., B.E., Manager, HITLAB India
Endotronix Care Management Solution: Improving CHF Management Using Wireless and Cloud-Based Tools
Congestive heart failure (CHF) is a debilitating chronic condition requiring repeated clinical visits and hospitalizations. Many CHF patients face post-discharge complications, with cardiac functions not fully restored to pre-hospitalization levels.
For healthcare payers, treatment approaches to CHF are equally challenging and cost-intensive with more than one million hospitalizations annually across the United States alone among the 26 million afflicted worldwide. Moreover, with a treatment cost estimated at 31 billion USD, primarily comprising in-patient hospitalization costs, CHF contributes to the bulk of healthcare expenses for payers age 65 and over, and treatment costs are estimated to double by 2030.
Actual pressure within the heart itself is an accurate indicator of worsening CHF. However, technological challenges persist in measuring pressure-related parameters outside of a clinical setting, thwarting efforts to regularly monitor a patient’s condition and also reduce hospitalizations. Given that remotely monitored metrics such as blood pressure, heart rate, weight, and thoracic impedance haven’t been effective in reducing CHF related hospitalizations, this clearly outlines both the lack of ample predictive power in currently used approaches as well as the need for alternative methods of measurement.
The “Endotronix Care Management Solution,” developed by Chicago-based Endotronix, could pave the way for more accurate cardiac function measurements, leading to personalized patient care experiences. The proposed solution involves capturing pulmonary artery (PA) pressure data using a mobile device which would then be securely transmitted for review by the patient’s clinical care team. Coupled with Endotronix’s cloud-based outpatient management system that would enable care providers monitor patients’ pulmonary artery pressure, this solution aims to proactively improve patient convenience and quality of care while reducing overall CHF care costs.
Here is how the proposed solution would work:
· Collection – A tiny pressure sensor would be implanted in the patient’s pulmonary artery in a low-cost catheterization procedure. A portable and wireless “Endotronix reader” (roughly the size of a small tablet/smartphone) would be carried by the patient or kept at a convenient location. The reader would be switched on and held against the patient’s chest for about 20-30 seconds to obtain instantaneous PA pressure measurement.
· Transmission – The reader would transmit power wirelessly to the sensor, allowing for accurate measurement and transmission of PA pressure data back to the reader. The reader would then transmit this data securely to the patient’s healthcare provider using a wireless, secure link to the HIPAA-compliant Endotronix clinical care management software.
· Storage and Sharing - The system would immediately analyze patient data (near real-time on the Triage Dashboard), followed by Clinical Care Team monitoring; for data warranting urgent intervention or analysis, an alert would be raised, facilitating proactive management.
· Management and Usage – The Clinical Care Team will act to provide timely, personalized clinical interventions, using actionable data. Ranging from medication adjustments without clinical visits, to prescribing lifestyle modifications and optimized drug regimens for early treatment and reduced hospitalizations, such personalized care is expected to improve overall health outcomes.
Backed by the likes of Silicon Valley Bank, BioVentures, SV Life Sciences, Lumira Capital, Aperture Venture Partners, and OSF Ventures, Endotronix has successfully raised funding of 50 million USD to date. A recent Series C funding of 32 million USD would help fund feasibility studies of their implantable sensor and commercialization of their cloud-based outpatient management system.
Going forward, such patient-centric, digital solutions enabling timely detection and continuous physician-patient engagement are expected to significantly improve the management of chronic heart failure.
by Devmalya Sarkar, M.S., B.E., Manager, HITLAB India
The ReCIVA Breath Sampler: A reliable and reproducible breath analyzer to capture VOC biomarkers in breath samples
Type 1 diabetes, colorectal cancer, lung cancer, obesity, lactose and fructose intolerance, tuberculosis, chronic kidney disease, liver cirrhosis, influenza, asthma, bronchitis - what do these diseases have in common? Not much, you’d say. Many of these conditions often go undetected until relevant symptoms and/or comorbidities surface. Did you know that patients in all of the above-mentioned cases carry trace amounts of distinctive biomarkers in their breath? Detecting these markers may allow doctors to non-invasively diagnose such diseases at an early stage, even before symptoms arise.
RockHealth’s “Invention of the Year,” the ReCIVA (Respiration Collector for In Vitro Analysis) Breath Sampler, a breath analyzer for disease, has set out to save 100,000 lives and $1.5B in healthcare costs by 2020, focusing on non-invasive diagnostics for cancer as well as inflammatory and infectious diseases.
Developed by Cambridge, UK based Owlstone Medical, the device leverages proprietary and proven Field Asymmetric Ion Mobility Spectrometry (FAIMS) technology. FAIMS measures volatile organic compound (VOC) metabolites in patients’ breath or bodily fluids. The measurement of VOC biomarkers allows non-invasive diagnosis of disease at a very early stage, enabling more effective treatment and better patient outcomes.
Exhaled VOCs are indicative of a broad range of pathological and physiological processes, occurring both in airways and also systemically throughout the body. These VOC biomarkers are used in various applications: early detection of disease in asymptomatic subjects, therapy stratification, monitoring of therapy response, and disease activity. Challenges with regard to reliability, reproducibility, transport, and storage of collected samples have limited the adoption of breath-based VOC sampling in clinical research and practice. To overcome these limitations, the ReCIVA breath sampler has been developed as a reliable and cost-effective solution.
Developed in conjunction with a multi-disciplinary group of researchers, the ReCIVA provides a method to reproducibly and reliably capture breath samples for analysis. The system is currently being deployed as part of Owlstone's LuCID lung cancer detection project. The device has also been awarded the "Conformité Européene" ("European Conformity" or CE mark) certification and is currently in use in over 60 academic research groups and clinical labs around the world.
In particular, the CE mark of approval for the pediatric version of ReCIVA enhances the scope of breath testing in the difficult-to-manage group of child asthma patients. Both the adult and pediatric versions of the “breathalyzer” are now being used in EMBER (East Midlands Breathomics Pathology Node), a £2.5M project funded by the Medical Research Council (MRC) and the Engineering and Physical Sciences Research Council (EPSRC). The primary aim of EMBER is to develop breath-based systems for molecular pathology of disease and clinically validate “breathomics” as a new diagnostic modality.
Salient features of the ReCIVA include flexible breath collection, reproducible sampling, options for real-time or timed analysis, high patient safety and comfort, and customizability.
In addition to being non-invasive and pain free, the biggest advantage of breath sampling and analysis technology in disease detection lies in its ability to utilize specific VOCs of interest in different breath fractions, specific to the disease under investigation. As such, the ReCIVA aims to reportedly diagnose cancer and other diseases earlier than existing tests.
With an inherent potential to diagnose a wide array of conditions, and supported by growing clinical evidence and standardized methods, new technologies such as the ReCIVA could take us a step closer to wider adoption of advanced and timely diagnostic techniques, allowing for improved survival rates as well as reduced treatment costs.